Schwachman-Diamond syndrome is a dubious disease in the field of blood tumors, with complex clinical outcomes and often involving multi-system congestion. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging checks, laboratory checks and pathological activation.
The platform can help align teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of congenital malignant Shwachman-Diamond syndrome require individualized treatment regimens, typically including multidimensional drug therapy, rehabilitation interventions, regular follow-up, and more. In recent years, with the development of targeted therapy, immune regulation therapy, and precision medicine, significant improvements have been made in many previously difficult-to-treat blood tumor diseases.
Therapeutic and adverse reactions need to be closely monitored throughout the treatment process, and regimens adjusted in a timely manner according to changes in the condition. The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of blood oncology, to provide the following services to patients: 1. Remote pre-diagnosis: pre-examination of medical history, precise diagnostic directions and medical advice by a team of experts; 2.
Interviews in China: arranging face-to-face diagnosis with authoritative experts, developing personalized treatment programs; 3. Full-service: providing one-stop services: providing medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.
Support for remote pre-diagnosis, visiting interviews, full translation and escort.